CTMX

CytomX Therapeutics (CTMX)

CytomX Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:CTMX

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/23	05:05	GlobeNewswire Inc.	CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/18	06:36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/18	06:36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/18	06:34	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/18	06:32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/18	06:31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/18	05:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/17	05:15	GlobeNewswire Inc.	CytomX Therapeutics Announces New Employment Inducement Grants	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/14	05:00	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/09	05:41	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/09	05:10	GlobeNewswire Inc.	CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/09	05:10	GlobeNewswire Inc.	CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/09	05:04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/09	05:01	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/08	05:15	GlobeNewswire Inc.	CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/05/01	21:00	GlobeNewswire Inc.	CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/04/08	21:00	GlobeNewswire Inc.	CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/04/03	21:00	GlobeNewswire Inc.	CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/03/21	21:00	GlobeNewswire Inc.	CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/03/18	21:00	GlobeNewswire Inc.	CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/03/12	05:30	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/03/12	05:10	GlobeNewswire Inc.	CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/03/12	05:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/03/12	05:00	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/03/11	19:39	IH Market News	U.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge Higher	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/03/04	22:00	GlobeNewswire Inc.	CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/02/27	22:00	GlobeNewswire Inc.	CytomX Therapeutics to Present at Upcoming March Investor Conferences	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/01/24	22:00	GlobeNewswire Inc.	CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/01/20	10:44	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CTMX	CytomX Therapeutics Inc
2024/01/20	10:41	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CTMX	CytomX Therapeutics Inc